Trial Profile
Nucleoside-Sparing Combination Therapy With Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL) vs. Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC) in Antiretroviral-Naive Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Raltegravir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- 30 Jan 2017 Results reporting viral kinetics from CCTG589 (n=51) and an apriori planned immunologic sub-study (n=28) , published in the HIV Clinical Trials
- 01 Apr 2014 Status changed from active, no longer recruiting to completed.
- 20 Jul 2011 Results presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.